Phase II

Phase II clinical trials evaluate investigational therapies in patients with the target disease, assessing both efficacy and safety in populations ranging from 100-300 participants. These pivotal studies provide the first substantial evidence that a drug candidate produces intended therapeutic effects while maintaining acceptable tolerability, determining whether further development is scientifically and commercially justified.

Researchers design Phase II trials to identify optimal dosing regimens, explore multiple disease subtypes, and establish appropriate endpoints for definitive Phase III studies, often employing randomised controlled designs. Biomarker analyses frequently accompany Phase II studies, identifying patient subsets most likely to benefit. The biopharmaceutical industry recognises Phase II as the most critical decision point in drug development, with only 33% of candidates historically advancing to Phase III. Innovative trial designs including adaptive approaches, seamless Phase II/III transitions, and platform trials have emerged to improve efficiency and success rates. Organisations leverage real-world data and advanced analytics to optimise Phase II strategies, accelerating delivery of breakthrough therapies while managing development risks across diverse therapeutic pipelines.